Nuclear Medicine/Radiopharmaceuticals Market

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

Report Code: PH 3590 Jan, 2020, by marketsandmarkets.com

[230 Pages Report] The nuclear medicine market is expected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

Nuclear Medicine/Radiopharmaceuticals Market

The alpha emitters segment is expected to command the largest therapeutic nuclear medicine market share in 2019

Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. In 2013, the FDA approved the first and only product for alpha emitters in the market, launched by Bayer AG under the name Xofigo (a Ra-223 dichloride molecule). The North American market for Ra-223 is expected to command the largest share owing to its targeted properties over beta emitters and being the only alpha-emitter product available in the market.

The thyroid applications segment is expected to register the highest growth during the forecast period

Based on application, the  nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

By procedural volume assessment, the diagnostic procedures segment is expected to account for the largest share of the market in 2019

Based on procedural volume assessment, the nuclear medicine market is segmented into diagnostic and therapeutic procedures. Diagnostic procedures account for the larger share, as diagnostic radioisotopes find wider demand and use as compared to therapeutic radioisotopes. Since the introduction of nuclear medicine, SPECT diagnosis has been preferred over other radiopharmaceutical procedures. Due to looming uncertainties in the production of reactor-based Mo-99, the radiopharmaceuticals market is witnessing a shift toward PET procedures. Other major factors responsible for this trend are advancements in radiotracers for PET and the advent of hybrid imaging systems such as PET-CT and PET-MRI.

Nuclear Medicine/Radiopharmaceuticals Market

North America accounted for the largest share of the nuclear medicine market in 2018

The global nuclear medicine market has been categorized on the basis of four major regional segments—North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the region.

Key Market Players

Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacύbaώύ-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Scope of the Report

Report Metric

Details

Market size available for years

2018–2024

Base year considered

2018

Forecast period

2019–2024

Forecast unit

Value (USD)

Segments covered

Type, Application, Procedural Volume, and Region

Geographies covered

North America (US & Canada), Europe (Germany, France, UK, Italy, Spain, and RoE), APAC(Japan, China, and RoAPAC), and RoW (Latin America, Middle East, and Africa)

Companies covered

Major 20 players included, including Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacύbaώύ-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), JSC Isotope (Russia), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Jubilant DraxImage (Canada), PharmaLogic (US), Institute of Isotopes Co., Ltd. (Hungary), Sinotau Pharmaceuticals (China), Isotopia Molecular Imaging Limited (Israel), SHINE Medical Technologies (US), and Global Medical Solutions (US).

This research report categorizes the market based on type, application, procedural volume, and country.

By Type

  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
      • Technetium-99m
      • Thallium-201
      • Gallium-67
      • Iodine-123
      • Other SPECT Isotopes
    • PET Radiopharmaceuticals
      • F-18
      • Ru-82
      • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
      • Ra-223
    • Beta Emitters
      • Iodine-131
      • Yttrium-90
      • Samarium-153
      • Lutetium-177
      • Rhenium-186
      • Other Beta Emitters
  • Brachytherapy Isotopes
    • Iodine-125
    • Palladium-103
    • Cesium-131
    • Iridium-192
    • Other Brachytherapy Isotopes

By Application

  • Diagnostic Applications
    • SPECT Applications
      • Cardiology
      • Bone Scans
      • Thyroid Applications
      • Pulmonary Scans
      • Other SPECT Applications
    • PET Applications
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
    • Therapeutic Applications
      • Thyroid Indications
      • Bone Metastasis
      • Lymphoma
      • Endocrine Tumors
      • Other Indications

By Procedural Volume Assessment

  • Diagnostic Procedures
    • SPECT Procedures
    • PET Procedures
  • Therapeutic Procedures
    • Beta Emitter Procedures
    • Alpha Emitter Procedures
    • Brachytherapy Procedures

By Region

 North America

  • US
  • Canada

 Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)

 Asia Pacific

  • China
  • Japan
  • RoAPAC

Rest of the World (RoW)

Recent Developments:

  • In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.
  • In 2019, Eczacύbaώύ-Monrol and Telix Pharmaceuticals Limited (Australia) signed a manufacturing and distribution agreement. Under the terms of the agreement, Telix has appointed Eczacύbaώύ-Monrol as a radiopharmaceutical production partner and distributor in Turkey, the Middle East, and North Africa.
  • In 2019, Curium (France) and NRG (Netherlands) signed an agreement for the production of Molybdenum-99.

Key Questions Addressed by the Report

  • Which type segment will dominate the nuclear medicine market in the future?
  • Which application segment will dominate the nuclear medicine market in the future?
  • Emerging countries offer immense opportunities for the growth and adoption of nuclear medicine; will this scenario continue in the coming five years?
  • Where will all the advancements in technology offered by various companies take the industry in the mid- to long-term?
  • What are the upcoming products in the nuclear medicine market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 26)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Market Scope
           1.2.2 Markets Covered
           1.2.3 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 30)
    2.1 Research Data
    2.2 Research Methodology Steps
           2.2.1 Secondary Data
                    2.2.1.1 Secondary Sources
           2.2.2 Primary Data
                    2.2.2.1 Primary Sources
                    2.2.2.2 Key Insights From Primary Sources
           2.2.3 Market Size Estimation Methodology
           2.2.4 Revenue Mapping-Based Market Estimation
    2.3 Market Data Estimation and Triangulation
    2.4 Assumptions of the Study

3 Executive Summary (Page No. - 40)

4 Premium Insights (Page No. - 43)
    4.1 Nuclear Medicine Market Overview
    4.2 North America: Nuclear Medicine Market, By Type and Country (2019)
    4.3 Diagnostic Procedures Market, By Type, 2019 vs 2024
    4.4 Therapeutic Nuclear Medicine Market, By Type, 2019 vs 2024

5 Market Overview (Page No. - 46)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Incidence and Prevalence of Target Conditions
                    5.2.1.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
                    5.2.1.3 Initiatives to Reduce the Demand-Supply Gap of Mo-99
           5.2.2 Restraints
                    5.2.2.1 Short Half-Life of Radiopharmaceuticals
           5.2.3 Opportunities
                    5.2.3.1 Use of Radiopharmaceuticals in Neurological Applications
           5.2.4 Challenges
                    5.2.4.1 Hospital Budget Cuts and High Equipment Prices

6 Nuclear Medicine/Radiopharmaceuticals Market, By Type (Page No. - 50)
    6.1 Introduction
    6.2 Diagnostic Nuclear Medicine
           6.2.1 SPECT Radiopharmaceuticals
                    6.2.1.1 TC-99m
                               6.2.1.1.1 TC-99m Commanded the Largest Share of the SPECT Radiopharmaceuticals Market in 2018
                    6.2.1.2 I-123
                               6.2.1.2.1 Reduced Exposure to Radiation and Lower Risk of Patients Developing Radiation-Induced Cancer to Drive the Demand for I-123
                    6.2.1.3 Tl-201
                               6.2.1.3.1 TI-201 Can Be A Potential Substitute to TC-99m
                    6.2.1.4 GA-67
                               6.2.1.4.1 Overall Sensitivity of A Gallium Scan is Approximately 80% as A Tumor-Imaging Agent, Which is A Key Factor Driving the Growth of the GA-67 Market
                    6.2.1.5 Other SPECT Isotopes
           6.2.2 PET Radiopharmaceuticals
                    6.2.2.1 F-18
                               6.2.2.1.1 F-18 Commanded the Largest Share of the PET Radiopharmaceuticals Market
                    6.2.2.2 Rb-82
                               6.2.2.2.1 Increasing Number of PET Procedures and High Accuracy Offered By the Rb-82 Isotope to Drive the Growth of This Market
                    6.2.2.3 Other PET Isotopes
    6.3 Therapeutic Nuclear Medicine
           6.3.1 Alpha Emitters
                    6.3.1.1 RA-223
                               6.3.1.1.1 Easy Production of RA-223 is A Key Advantage Driving Market Growth
           6.3.2 Beta Emitters
                    6.3.2.1 Iodine-131
                               6.3.2.1.1 Iodine-131 Accounted for the Largest Share of the Beta Emitters Market
                    6.3.2.2 Y-90
                               6.3.2.2.1 Increasing Applications in Treating Hepatocellular Carcinoma to Propel the Growth of This Segment
                    6.3.2.3 SM-153
                               6.3.2.3.1 Increasing Incidence of Bone Metastasis to Drive the Growth of This Segment
                    6.3.2.4 LU-177
                               6.3.2.4.1 Increasing Incidence of Neuroendocrine Cancer is A Key Factor Driving the Growth of This Segment
                    6.3.2.5 RE-186
                               6.3.2.5.1 RE-186 is Commonly Used for Bone Pain Relief
                    6.3.2.6 Other Beta Emitters
           6.3.3 Brachytherapy Isotopes
                    6.3.3.1 Iodine-125
                               6.3.3.1.1 I-125 Accounted for the Largest Share of the Brachytherapy Isotopes Market
                    6.3.3.2 Iridium-192
                               6.3.3.2.1 IR-192 is Used in Treating Prostate Cancer, Skin Cancer, Sarcoids, and Oral Cancer
                    6.3.3.3 Palladium-103
                               6.3.3.3.1 PD-103 is Best Suited to Treat Aggressive Tumors
                    6.3.3.4 Cesium-131
                               6.3.3.4.1 CS-131 is Commonly Used in Gynecological Applications
                    6.3.3.5 Other Brachytherapy Isotopes

7 Nuclear Medicine/Radiopharmaceuticals Market, By Application (Page No. - 97)
    7.1 Introduction
    7.2 Diagnostic Applications
           7.2.1 SPECT Applications
                    7.2.1.1 Cardiology
                               7.2.1.1.1 Rising Incidence of Cvd has Increased the Demand for Cardiac Diagnostic Scans
                    7.2.1.2 Bone Scans
                               7.2.1.2.1 Precision of SPECT in Bone Scanning has Driven Dependence on the Technology
                    7.2.1.3 Thyroid Applications
                               7.2.1.3.1 Introduction of Dual SPECT/CT Imaging is an Important Trend in the Thyroid Applications Segment
                    7.2.1.4 Pulmonary Scans
                               7.2.1.4.1 SPECT/CT has Shown High Accuracy and Sensitivity in Pulmonary Embolism Applications
                    7.2.1.5 Other SPECT Applications
           7.2.2 PET Applications
                    7.2.2.1 Oncology
                               7.2.2.1.1 Increasing Cancer Incidence Will Fuel Market Growth
                    7.2.2.2 Cardiology
                               7.2.2.2.1 Growing Preference for Fdg in Cardiac Imaging is Likely to Boost Market Growth
                    7.2.2.3 Neurology
                               7.2.2.3.1 Increasing Incidence of AD, Epilepsy, and Parkinson’s Disease is the Major Driver for the Growth of the PET Neurology Market
                    7.2.2.4 Other PET Applications
    7.3 Therapeutic Applications
           7.3.1 Thyroid Indications
                    7.3.1.1 Increasing Prevalence of Thyroid Disorders Will Fuel Market Growth
           7.3.2 Bone Metastasis
                    7.3.2.1 Introduction of Novel Therapies for Bone Metastasis Will Positively Impact the Market
           7.3.3 Endocrine Tumors
                    7.3.3.1 The US Dominates the Therapeutic Nuclear Medicine Market for Endocrine Tumor Applications
           7.3.4 Lymphoma
                    7.3.4.1 Development of New Isotopes for the Treatment of Lymphoma Presents Huge Growth Opportunities
           7.3.5 Other Indications

8 Nuclear Medicine/Radiopharmaceuticals Market: Procedural Volume Assessment (Page No. - 110)
    8.1 Introduction
    8.2 Diagnostic Procedures
           8.2.1 SPECT Procedures
           8.2.2 PET Procedures
    8.3 Therapeutic Procedures
           8.3.1 Beta Emitter Procedures
           8.3.2 Alpha Emitter Procedures
           8.3.3 Brachytherapy Procedures

9 Nuclear Medicine/Radiopharmaceuticals Market, By Region (Page No. - 117)
    9.1 Introduction
    9.2 North America
           9.2.1 US
                    9.2.1.1 The US Holds the Largest Share of the North American Market
           9.2.2 Canada
                    9.2.2.1 Investments to Secure Medical Isotope Supply are Likely to Boost Market Growth
    9.3 APAC
           9.3.1 Japan
                    9.3.1.1 Japan Dominates the APAC Nuclear Medicine Market
           9.3.2 China
                    9.3.2.1 High Incidence of Cancer and Strokes Will Support Market Growth in China
           9.3.3 Rest of Asia Pacific
    9.4 Europe
           9.4.1 Germany
                    9.4.1.1 The Well-Established Healthcare System in Germany is A Major Factor Supporting Market Growth in the Country
           9.4.2 France
                    9.4.2.1 France has A Favorable Reimbursement Scenario for Nuclear Imaging
           9.4.3 UK
                    9.4.3.1 Rising Demand for Nuclear Imaging and Growing Awareness Will Drive the Market in the UK
           9.4.4 Italy
                    9.4.4.1 Growing Prevalence of Cancer and Cvd are Likely to Drive Market Growth in Italy
           9.4.5 Spain
                    9.4.5.1 Initiatives By Semnim are Likely to have A Positive Impact on the Nuclear Medicine Market in Spain
           9.4.6 RoE
    9.5 Rest of the World

10 Competitive Landscape (Page No. - 178)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Competitive Leadership Mapping
             10.3.1 Visionary Leaders
             10.3.2 Innovators
             10.3.3 Dynamic Differentiators
             10.3.4 Emerging Companies
     10.4 Competitive Scenario
             10.4.1 Product Launches & Approvals
             10.4.2 Contracts
             10.4.3 Acquisitions
             10.4.4 Agreements, Partnerships, and Collaborations

11 Company Profiles (Page No. - 185)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 Cardinal Health
     11.2 Curium
     11.3 GE Healthcare
     11.4 Lantheus Medical Imaging, Inc.
     11.5 Bayer AG
     11.6 Bracco Imaging S.P.A.
     11.7 Eczacibasi-Monrol Nuclear Products
     11.8 Nordion, Inc. (A Subsidiary of Sterigenics International)
     11.9 Advanced Accelerator Applications (AAA) (A Part of Novartis)
     11.10 NTP Radioisotopes Soc, LTD. 
(A Subsidiary of South African Nuclear Energy Corporation)
     11.11 Joint Stock Company Isotope (Jsc Isotope)
     11.12 Northstar Medical Radioisotopes, LLC
     11.13 Eckert & Ziegler
     11.14 Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
     11.15 Pharmalogic
     11.16 Institute of Isotopes Co., LTD.
     11.17 Sinotau Pharmaceuticals Group
     11.18 Isotopia Molecular Imaging Limited
     11.19 Shine Medical Technologies
     11.20 Global Medical Solutions, LTD.
     11.21 Right to Win

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 221)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Available Customizations
     12.4 Related Reports
     12.5 Author Details


List of Tables (308 Tables)

Table 1 New Reactors Expected to Open During the Forecast Period
Table 2 Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 3 Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 4 Diagnostic Nuclear Medicine Market, By Region, 2017–2024 (USD Million)
Table 5 North America: Diagnostic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 6 Europe: Diagnostic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 7 APAC: Diagnostic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 8 Alternatives to Common TC-99m-Based Diagnostic Procedures in the Face of Severe TC-99m Shortages
Table 9 SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 10 SPECT Radiopharmaceuticals Market, By Region, 2017–2024 (USD Million)
Table 11 North America: SPECT Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 12 Europe: SPECT Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 13 APAC: SPECT Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 14 TC-99m Market, By Region, 2017–2024 (USD Million)
Table 15 North America: TC-99m Market, By Country, 2017–2024 (USD Million)
Table 16 Europe: TC-99m Market, By Country, 2017–2024 (USD Million)
Table 17 APAC: TC-99m Market, By Country, 2017–2024 (USD Million)
Table 18 I-123 Market, By Region, 2017–2024 (USD Million)
Table 19 North America: I-123 Market, By Country, 2017–2024 (USD Million)
Table 20 Europe: I-123 Market, By Country, 2017–2024 (USD Million)
Table 21 APAC: I-123 Market, By Country, 2017–2024 (USD Million)
Table 22 TI-201 Market, By Region, 2017–2024 (USD Million)
Table 23 North America: TI-201 Market, By Country, 2017–2024 (USD Million)
Table 24 Europe: TI-201 Market, By Country, 2017–2024 (USD Million)
Table 25 APAC: TI-201 Market, By Country, 2017–2024 (USD Million)
Table 26 GA-67 Market, By Region, 2017–2024 (USD Million)
Table 27 North America: GA-67 Market, By Country, 2017–2024 (USD Million)
Table 28 Europe: GA-67 Market, By Country, 2017–2024 (USD Million)
Table 29 APAC: GA-67 Market, By Country, 2017–2024 (USD Million)
Table 30 Other SPECT Isotopes Market, By Region, 2017–2024 (USD Million)
Table 31 North America: Other SPECT Isotopes Market, By Country, 2017–2024 (USD Million)
Table 32 Europe: Other SPECT Isotopes Market, By Country, 2017–2024 (USD Million)
Table 33 APAC: Other SPECT Isotopes Market, By Country, 2017–2024 (USD Million)
Table 34 PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 35 PET Radiopharmaceuticals Market, By Region, 2017–2024 (USD Million)
Table 36 North America: PET Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 37 Europe: PET Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 38 APAC: PET Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 39 F-18 Market, By Region, 2017–2024 (USD Million)
Table 40 North America: F-18 Market, By Country, 2017–2024 (USD Million)
Table 41 Europe: F-18 Market, By Country, 2017–2024 (USD Million)
Table 42 APAC: F-18 Market, By Country, 2017–2024 (USD Million)
Table 43 Rb-82 Market, By Region, 2017–2024 (USD Million)
Table 44 North America: Rb-82 Market, By Country, 2017–2024 (USD Million)
Table 45 Europe: Rb-82 Market, By Country, 2017–2024 (USD Million)
Table 46 APAC: Rb-82 Market, By Country, 2017–2024 (USD Million)
Table 47 Other PET Isotopes Market, By Region, 2017–2024 (USD Million)
Table 48 North America: Other PET Isotopes Market, By Country, 2017–2024 (USD Million)
Table 49 Europe: Other PET Isotopes Market, By Country, 2017–2024 (USD Million)
Table 50 APAC: Other PET Isotopes Market, By Country, 2017–2024 (USD Million)
Table 51 Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 52 Therapeutic Nuclear Medicine Market, By Region, 2017–2024 (USD Million)
Table 53 North America: Therapeutic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 54 Europe: Therapeutic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 55 APAC: Therapeutic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 56 RA-223 Market, By Region, 2017–2024 (USD Million)
Table 57 North America: RA-223 Market, By Country, 2017–2024 (USD Million)
Table 58 Europe: RA-223 Market, By Country, 2017–2024 (USD Million)
Table 59 APAC: RA-223 Market, By Country, 2017–2024 (USD Million)
Table 60 Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 61 Beta Emitters Market, By Region, 2017–2024 (USD Million)
Table 62 North America: Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 63 Europe: Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 64 APAC: Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 65 I-131 Market, By Region, 2017–2024 (USD Million)
Table 66 North America: I-131 Market, By Country, 2017–2024 (USD Million)
Table 67 Europe: I-131 Market, By Country, 2017–2024 (USD Million)
Table 68 APAC: I-131 Market, By Country, 2017–2024 (USD Million)
Table 69 Y-90 Market, By Region, 2017–2024 (USD Million)
Table 70 North America: Y-90 Market, By Country, 2017–2024 (USD Million)
Table 71 Europe: Y-90 Market, By Country, 2017–2024 (USD Million)
Table 72 APAC: Y-90 Market, By Country, 2017–2024 (USD Million)
Table 73 SM-153 Market, By Region, 2017–2024 (USD Million)
Table 74 North America: SM-153 Market, By Country, 2017–2024 (USD Million)
Table 75 Europe: SM-153 Market, By Country, 2017–2024 (USD Million)
Table 76 APAC: SM-153 Market, By Country, 2017–2024 (USD Million)
Table 77 LU-177 Market, By Region, 2017–2024 (USD Million)
Table 78 North America: LU-177 Market, By Country, 2017–2024 (USD Million)
Table 79 Europe: LU-177 Market, By Country, 2017–2024 (USD Million)
Table 80 APAC: LU-177 Market, By Country, 2017–2024 (USD Million)
Table 81 RE-186 Market, By Region, 2017–2024 (USD Million)
Table 82 North America: RE-186 Market, By Country, 2017–2024 (USD Million)
Table 83 Europe: RE-186 Market, By Country, 2017–2024 (USD Million)
Table 84 APAC: RE-186 Market, By Country, 2017–2024 (USD Million)
Table 85 Other Beta Emitters Market, By Region, 2017–2024 (USD Million)
Table 86 North America: Other Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 87 Europe: Other Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 88 APAC: Other Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 89 Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 90 Brachytherapy Isotopes Market, By Region, 2017–2024 (USD Million)
Table 91 North America: Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 92 Europe: Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 93 APAC: Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 94 I-125 Market, By Region, 2017–2024 (USD Million)
Table 95 North America: I-125 Market, By Country, 2017–2024 (USD Million)
Table 96 Europe: I-125 Market, By Country, 2017–2024 (USD Million)
Table 97 APAC: I-125 Market, By Country, 2017–2024 (USD Million)
Table 98 IR-192 Market, By Region, 2017–2024 (USD Million)
Table 99 North America: IR-192 Market, By Country, 2017–2024 (USD Million)
Table 100 Europe: IR-192 Market, By Country, 2017–2024 (USD Million)
Table 101 APAC: IR-192 Market, By Country, 2017–2024 (USD Million)
Table 102 PD-103 Market, By Region, 2017–2024 (USD Million)
Table 103 North America: PD-103 Market, By Country, 2017–2024 (USD Million)
Table 104 Europe: PD-103 Market, By Country, 2017–2024 (USD Million)
Table 105 APAC: PD-103 Market, By Country, 2017–2024 (USD Million)
Table 106 CS-131 Market, By Region, 2017–2024 (USD Million)
Table 107 North America: CS-131 Market, By Country, 2017–2024 (USD Million)
Table 108 Europe: CS-131 Market, By Country, 2017–2024 (USD Million)
Table 109 APAC: CS-131 Market, By Country, 2017–2024 (USD Million)
Table 110 Other Brachytherapy Isotopes Market, By Region, 2017–2024 (USD Million)
Table 111 North America: Other Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 112 Europe: Other Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 113 APAC: Other Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 114 Nuclear Medicine Market, By Application, 2017–2024 (USD Million)
Table 115 Diagnostic Applications Market, By Type, 2017–2024 (USD Million)
Table 116 SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 117 SPECT Applications Market, By Region, 2017–2024 (USD Million)
Table 118 SPECT Cardiology Applications Market, By Region, 2017–2024 (USD Million)
Table 119 SPECT Bone Scan Applications Market, By Region, 2017–2024 (USD Million)
Table 120 SPECT Thyroid Applications Market, By Region, 2017–2024 (USD Million)
Table 121 SPECT Pulmonary Scan Applications Market, By Region, 2017–2024 (USD Million)
Table 122 Other SPECT Applications Market, By Region, 2017–2024 (USD Million)
Table 123 PET Applications Market, By Type, 2017–2024 (USD Million)
Table 124 PET Applications Market, By Region, 2017–2024 (USD Million)
Table 125 PET Oncology Applications Market, By Region, 2017–2024 (USD Million)
Table 126 PET Cardiology Applications Market, By Region, 2017–2024 (USD Million)
Table 127 PET Neurology Applications Market, By Region, 2017–2024 (USD Million)
Table 128 Other PET Applications Market, By Region, 2017–2024 (USD Million)
Table 129 Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 130 Therapeutic Applications Market, By Region, 2017–2024 (USD Million)
Table 131 Therapeutic Applications Market for Thyroid Indications, By Region, 2017–2024 (USD Million)
Table 132 Therapeutic Applications Market for Bone Metastasis, By Region, 2017–2024 (USD Million)
Table 133 Therapeutic Applications Market for Endocrine Tumors, By Region, 2017–2024 (USD Million)
Table 134 Therapeutic Applications Market for Lymphoma, By Region, 2017–2024 (USD Million)
Table 135 Therapeutic Applications Market for Other Indications, By Region, 2017–2024 (USD Million)
Table 136 Nuclear Medicine Market, By Procedure, 2017–2024 (Thousand Procedures)
Table 137 Nuclear Medicine Market, By Region, 2017–2024 (Thousand Procedures)
Table 138 Diagnostic Procedures Market, By Type, 2017–2024 (Thousand Procedures)
Table 139 Diagnostic Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 140 SPECT Procedures Market, By Radioisotope 2017–2024 (Thousand Procedures)
Table 141 SPECT Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 142 PET Procedures Market, By Radioisotope, 2017–2024 (Thousand Procedures)
Table 143 PET Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 144 Therapeutic Procedures Market, By Type, 2017–2024 (Thousand Procedures)
Table 145 Therapeutic Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 146 Beta Emitter Procedures Market, By Radioisotope, 2017–2024 (Thousand Procedures)
Table 147 Beta Emitter Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 148 Alpha Emitter Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 149 Brachytherapy Procedures Market, By Radioisotope, 2017–2024 (Thousand Procedures)
Table 150 Brachytherapy Procedures Market, By Region, 2017–2024 (Thousand Procedures)
Table 151 Nuclear Medicine Market, By Region, 2017–2024 (USD Million)
Table 152 North America: Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 153 North America: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 154 North America: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 155 North America: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 156 North America: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 157 North America: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 158 North America: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 159 North America: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 160 North America: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 161 North America: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 162 North America: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 163 US: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 164 US: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 165 US: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 166 US: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 167 US: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 168 US: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 169 US: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 170 US: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 171 US: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 172 US: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 173 Canada: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 174 Canada: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 175 Canada: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 176 Canada: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 177 Canada: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 178 Canada: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 179 Canada: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 180 Canada: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 181 Canada: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 182 Canada: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 183 APAC: Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 184 APAC: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 185 APAC: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 186 APAC: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 187 APAC: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 188 APAC: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 189 APAC: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 190 APAC: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 191 APAC: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 192 APAC: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 193 APAC: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 194 Japan: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 195 Japan: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 196 Japan: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 197 Japan: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 198 Japan: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 199 Japan: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 200 Japan: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 201 Japan: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 202 Japan: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 203 Japan: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 204 China: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 205 China: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 206 China: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 207 China: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 208 China: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 209 China: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 210 China: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 211 China: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 212 China: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 213 China: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 214 RoAPAC: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 215 RoAPAC: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 216 RoAPAC: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 217 RoAPAC: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 218 RoAPAC: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 219 RoAPAC: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 220 RoAPAC: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 221 RoAPAC: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 222 RoAPAC: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 223 RoAPAC: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 224 Europe: Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 225 Europe: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 226 Europe: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 227 Europe: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 228 Europe: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 229 Europe: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 230 Europe: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 231 Europe: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 232 Europe: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 233 Europe: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 234 Europe: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 235 Germany: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 236 Germany: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 237 Germany: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 238 Germany: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 239 Germany: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 240 Germany: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 241 Germany: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 242 Germany: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 243 Germany: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 244 Germany: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 245 France: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 246 France: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 247 France: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 248 France: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 249 France: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 250 France: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 251 France: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 252 France: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 253 France: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 254 France: Therapeutic Applications Market, By Indication, 2017–2024 (USD Million)
Table 255 UK: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 256 UK: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 257 UK: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 258 UK: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 259 UK: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 260 UK: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 261 UK: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 262 UK: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 263 UK: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 264 UK: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 265 Italy: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 266 Italy: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 267 Italy: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 268 Italy: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 269 Italy: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 270 Italy: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 271 Italy: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 272 Italy: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 273 Italy: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 274 Italy: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 275 Spain: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 276 Spain: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 277 Spain: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 278 Spain: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 279 Spain: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 280 Spain: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 281 Spain: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 282 Spain: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 283 Spain: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 284 Spain: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 285 RoE: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 286 RoE: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 287 RoE: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 288 RoE: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 289 RoE: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 290 RoE: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 291 RoE: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 292 RoE: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 293 RoE: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 294 RoE: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 295 RoW: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 296 RoW: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 297 RoW: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 298 RoW: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 299 RoW: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 300 RoW: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 301 RoW: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 302 RoW: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 303 RoW: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 304 RoW: Therapeutic Applications Market, By Type, 2017–2024 (USD Million)
Table 305 Product Launches & Approvals (2017–2019)
Table 306 Contracts (2017–2019)
Table 307 Acquisitions (2017–2019)
Table 308 Agreements, Partnerships, and Collaborations (2017–2019)


List of Figures (25 Figures)

Figure 1 Research Methodology: Nuclear Medicine Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Data Triangulation Methodology
Figure 6 Nuclear Medicine Market, By Type, 2019 vs 2024 (USD Million)
Figure 7 SPECT Applications Market, By Type, 2019 vs 2024 (USD Million)
Figure 8 PET Applications Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Therapeutic Applications Market, By Type, 2019 vs 2024 (USD Million)
Figure 10 High Prevalence of Cancer to Drive the Market During the Forecast Period
Figure 11 The US Accounted for the Largest Share of the Nuclear Medicine Market
Figure 12 SPECT Procedures to Account for the Largest Market Share During the Forecast Period
Figure 13 Beta Emitters to Account for the Largest Share of the Therapeutic Nuclear Medicine Market During the Forecast Period
Figure 14 Nuclear Medicine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 15 North America to Dominate the Nuclear Medicine Market in 2018
Figure 16 North America: Nuclear Medicine Market Snapshot
Figure 17 APAC: Nuclear Medicine Market Snapshot
Figure 18 Key Developments in the Nuclear Medicine Market, 2017–2019
Figure 19 Market Share Analysis, By Key Player, 2018
Figure 20 Nuclear Medicine Market: Competitive Leadership Mapping (2018)
Figure 21 Cardinal Health: Company Snapshot (2018)
Figure 22 GE Healthcare: Company Snapshot (2018)
Figure 23 Lantheus Medical Imaging, Inc.: Company Snapshot (2018)
Figure 24 Bayer AG: Company Snapshot (2018)
Figure 25 Eckert & Ziegler: Company Snapshot (2018)

The study involved four major activities in estimating the current size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as D&B, Bloomberg Businessweek, and Factiva have been referred to, to identify and collect information for the nuclear medicine market study. These secondary sources included annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold standard & silver standard websites, regulatory bodies, and databases.

Primary Research

The nuclear medicine market comprises several stakeholders such as radiopharmaceutical manufacturers and distributors, healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies), medical device vendors/service providers, research institutes, and research and consulting firms. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Mentioned below is the breakdown of primary respondents:

Nuclear Medicine/Radiopharmaceuticals Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall nuclear medicine market size-using the market size estimation processes as explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the nuclear medicine industry.

Report Objectives

  • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedural volume, and region
  • To provide detailed information regarding the major factors influencing the growth of this market (such as drivers, restraints, and opportunities)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall nuclear medicine market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to North America, Europe, the Asia Pacific, and the Rest of the World
  • To strategically analyze the market structure and profile key players and their core competencies in the nuclear medicine market

To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, and collaborations in the nuclear medicine market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the Contrast media/contrast agents market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the software portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Report Code
PH 3590
Published ON
Jan, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine/Radiopharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home